BIND Therapeutics Set To Revolutionize Drug Treatment As Clinical Data Continues To Impress
- Next-generation Accurin polymer nanoparticles represent the future of drug delivery technology by increasing efficacy and decreasing toxic side effects.
- Lucrative partnerships with Amgen, Pfizer and AstraZeneca yielding remarkable results.
- Impressive clinical responses for BIND-014 in a wide variety of tumor types that had previously failed several treatments.
- This is a rare opportunity for investors to get a company with strong partnerships and novel drug candidates at a big discount.